Jade Biosciences, Inc. financial data

Symbol
JBIO on Nasdaq
Location
221 Crescent St., Building 23, Suite 105, Waltham, MA
Fiscal year end
December 31
Latest financial report
Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 979 % +38%
Debt-to-equity 66.9 % +98.5%
Return On Equity -200 % -51%
Return On Assets -86.7 % -56.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46M shares +59.3%
Common Stock, Shares, Outstanding 32.6M shares +13%
Entity Public Float 23M USD -90.1%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39.6M shares +1154%
Weighted Average Number of Shares Outstanding, Diluted 39.6M shares +1154%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22M USD +62.1%
General and Administrative Expense 29M USD +171%
Operating Income (Loss) -93M USD -49.4%
Nonoperating Income (Expense) 3.64M USD +99.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -125M USD -107%
Earnings Per Share, Basic 2 USD/shares +90.7%
Earnings Per Share, Diluted 2 USD/shares +90.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 50.1M USD +61%
Cash, Cash Equivalents, and Short-term Investments 76.2M USD -23.3%
Assets, Current 201M USD +122%
Property, Plant and Equipment, Net 176K USD +1157%
Operating Lease, Right-of-Use Asset 740K USD +186%
Other Assets, Noncurrent 174K USD +115%
Assets 202M USD +123%
Accounts Payable, Current 1.35M USD +48.7%
Employee-related Liabilities, Current 3.1M USD -21.5%
Accrued Liabilities, Current 14M USD
Liabilities, Current 22.4M USD +117%
Operating Lease, Liability, Noncurrent 747K USD +822%
Liabilities 23.1M USD +121%
Accumulated Other Comprehensive Income (Loss), Net of Tax 29K USD -87.1%
Retained Earnings (Accumulated Deficit) -142M USD +37.4%
Stockholders' Equity Attributable to Parent 179M USD
Liabilities and Equity 202M USD +123%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.9M USD +89.9%
Net Cash Provided by (Used in) Financing Activities 25.4M USD
Net Cash Provided by (Used in) Investing Activities 60M USD +45.5%
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 32.6M shares +13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 35.1M USD
Deferred Tax Assets, Valuation Allowance 60.2M USD +38.1%
Deferred Tax Assets, Gross 60.2M USD +37.5%
Operating Lease, Liability 867K USD +60.6%
Depreciation 4K USD -85.7%
Payments to Acquire Property, Plant, and Equipment 16K USD -42.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -89.3M USD -48.2%
Lessee, Operating Lease, Liability, to be Paid 1.17M USD +110%
Operating Lease, Liability, Current 312K USD -29.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 231K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 226K USD -6.61%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 305K USD +1594%
Lessee, Operating Lease, Liability, to be Paid, Year Three 236K USD
Deferred Tax Assets, Operating Loss Carryforwards 23.9M USD +47.7%
Preferred Stock, Shares Issued 12.6K shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.16M USD +42.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 240K USD
Operating Lease, Payments 108K USD -15%
Additional Paid in Capital 322M USD +4.51%
Preferred Stock, Shares Outstanding 12.6K shares
Deferred Tax Assets, Net of Valuation Allowance 43K USD -79.1%
Share-based Payment Arrangement, Expense 10.6M USD -20.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%